The fragile kidneys of preterm infants face a complex and underexplored threat from the patent ductus arteriosus (PDA), a cardiac condition whose implications extend far beyond the heart itself. Recent research sheds new light on how the physiological disturbances of PDA influence neonatal kidney health, unraveling a web of interactions that may predetermine chronic kidney disease (CKD) risk years down the line. This emerging narrative calls into question traditional perspectives on PDA management and invites a reevaluation of long-term renal outcomes in these vulnerable infants.
Premature birth, particularly prior to 28 weeks of gestation, predisposes neonates to an alarmingly increased risk of kidney disease in later life. Statistics reveal that these infants are two to four times more likely to develop CKD, with early signs detectable as soon as two years of age. The kidney’s vulnerability in this population is not merely a consequence of underdevelopment but results from multifaceted etiologies that include shared risk factors overlapping with acute kidney injury (AKI). These risk factors encompass hypoxia, hemodynamic instability, and exposure to nephrotoxic medications, converging to sabotage nephrogenesis and kidney resilience.
Amidst these challenges, the presence of a PDA introduces additional hemodynamic complications. For the uninitiated, the ductus arteriosus is a fetal blood vessel that connects the pulmonary artery to the aorta, allowing fetal blood to bypass the non-ventilated lungs. Normally, this vessel closes in the immediate postnatal period; however, in many preterm infants, the ductus remains patent. This persistent shunt creates systemic and pulmonary blood flow imbalances that can strain immature organs. The kidney, highly sensitive to hemodynamic shifts, may suffer from altered perfusion, escalating the risk of injury and long-term dysfunction.
Despite the plausibility of these effects, the direct link between PDA pathophysiology and long-term kidney outcomes has remained elusive. Only recently has research explicitly focused on understanding how PDA and its management techniques impact renal function beyond the neonatal period. In one pivotal retrospective study, researchers compared renal outcomes at two years of age in infants treated for PDA versus those who remained untreated. Surprisingly, the findings demonstrated no significant difference in estimated glomerular filtration rate (eGFR) or albumin-to-creatinine ratios, well-established measures of kidney function.
However, the study unveiled a fascinating paradox—infants who received PDA treatment exhibited notably lower incidences of hypertension, defined as systolic blood pressure above the 90th percentile for their age. This observation suggests that medical or surgical closure of the PDA may confer protective effects not immediately visible through conventional renal biomarkers. Hypertension, a significant risk factor for progressive CKD, when mitigated, could indicate more subtle nephron preservation or improved systemic vascular regulation influenced by PDA management. These findings underscore the complexity of the PDA-kidney relationship, hinting that benefits of intervention may transcend traditional renal function metrics.
Yet, these valuable insights come with important caveats. The study’s retrospective design inherently limits the ability to establish causation, and the absence of comprehensive echocardiographic data to grade PDA shunt severity reduces the precision of comparisons. Additionally, the heterogeneity in treatment protocols—ranging from conservative watchful waiting to pharmacological and surgical intervention—complicates the interpretation of results. Such methodological constraints highlight the urgent need for prospective, controlled trials with standardized assessments to unravel the mechanistic pathways linking PDA physiology to renal health.
At the crux of the matter is the concept of nephron endowment— the total number of functional filtering units formed during kidney development. Prematurity already truncates nephrogenesis, which normally continues until about 36 weeks gestation. PDA-induced circulatory variations could exacerbate nephron loss or malformation, effectively “stealing nephrons” and compromising kidney reserve. Compounding this effect, hemodynamic instability can precipitate recurrent kidney ischemia, inflammation, and fibrosis, creating a protracted trajectory toward CKD. Understanding how PDA affects nephron trajectory represents a frontier in perinatal nephrology.
Unfortunately, longitudinal data extending beyond early childhood into adulthood are nearly nonexistent, leaving a critical knowledge gap regarding the lifelong kidney consequences of PDA. Given that CKD and hypertension carry significant morbidity and mortality, elucidating these pathways could guide neonatal care paradigms to optimize both heart and kidney protection. The potential for early PDA interventions to recalibrate risk profiles holds profound implications for clinical guidelines and parental counseling alike.
Emerging evidence also calls for a multidisciplinary approach integrating neonatologists, pediatric nephrologists, and cardiologists to tailor PDA management according to individual risk profiles. Echocardiographic measures of shunt volume and impact on systemic blood flow could inform decisions to intervene early versus monitor conservatively. Such tailored strategies might mitigate renal insults without exposing infants to unnecessary treatment risks, balancing cardiac and renal outcomes sensitively.
Pharmacologic agents used to close the PDA, such as indomethacin or ibuprofen, carry their own nephrotoxic potential, complicating the risk-benefit calculus. Therefore, innovations in therapeutic modalities that minimize renal side effects are eagerly awaited. Additionally, the role of supportive care measures, such as optimizing fluid management and avoiding nephrotoxins, remains foundational in safeguarding the fragile kidneys of preterm infants.
Intriguingly, there is growing interest in incorporating biomarkers of kidney injury and repair to monitor subclinical changes in renal health. Novel urinary and blood markers could help detect early kidney stress before overt dysfunction emerges, allowing timely adjustments in treatment strategies. In research settings, these biomarkers may elucidate the mechanistic underpinnings of PDA-related nephron loss or preservation over time.
From a broader perspective, this evolving understanding of PDA’s impact on renal health challenges us to reconceptualize neonatal care beyond survival and immediate outcomes. The intertwined fate of the heart and kidneys in preterm infants exemplifies the principle that organ systems do not exist in isolation. Thus, comprehensive models of neonatal care must integrate insights from cardiology, nephrology, and developmental biology to ensure holistic, long-term health optimization.
As science advances, it becomes increasingly clear that PDA is not merely a transient cardiac anomaly but a potential origin point for chronic renal vulnerability. This paradigm shift opens avenues for preventive strategies, early interventions, and personalized medicine approaches designed to preserve nephron number and function. Ultimately, these efforts aim to break the chain linking prematurity, PDA, and CKD, offering hope for improved quality of life decades after the neonatal period.
In light of these developments, the medical community and researchers are called upon to prioritize longitudinal cohort studies that track renal outcomes into adolescence and adulthood. Such data will be instrumental in validating early findings and refining treatment algorithms. Additionally, investment in experimental models that simulate PDA physiology and its renal repercussions can expedite discovery of protective mechanisms and therapeutic targets.
The unfolding story of PDA and neonatal kidney health exemplifies the intricate interplay of developmental physiology and disease. It urges vigilance in clinical practice and fuels a quest for knowledge that promises to transform care for the smallest and most vulnerable patients—ushering in a new era where saving nephrons today safeguards the lives and wellbeing of adults tomorrow.
Subject of Research: Impact of patent ductus arteriosus physiology on neonatal kidney health and long-term kidney outcomes.
Article Title: Stealing nephrons—a review on how patent ductus arteriosus physiology impacts neonatal kidney health.
Article References:
Condit, P.E., Harshman, L.A., Soranno, D.E. et al. Stealing nephrons—a review on how patent ductus arteriosus physiology impacts neonatal kidney health. J Perinatol (2025). https://doi.org/10.1038/s41372-025-02477-w
Image Credits: AI Generated
DOI: 05 November 2025
Keywords: Patent Ductus Arteriosus, Neonatal Kidney Health, Prematurity, Chronic Kidney Disease, Nephrogenesis, Hypertension, Neonatal Cardiology, Renal Function, Neonatal Intensive Care, Pediatric Nephrology
Tags: Acute Kidney Injury in Premature BabiesChronic Kidney Disease DevelopmentHemodynamic Instability and Kidney FunctionImpacts of PDA on Renal OutcomesKidney Health Risks in NewbornsLong-term Health Consequences of PDAManagement of Patent Ductus ArteriosusNeonatal Kidney VulnerabilityNephrotoxic Medications in NeonatesPatent Ductus Arteriosus in Preterm InfantsPreterm Birth and Kidney DiseaseRisk Factors for Kidney Disease in Inf
